Christobel Selecky, Director at ImmunityBio, sold IBRX on Jun 29, 2026
Data as of Oct 16
- Traded
- Jun 29, 2026
- Disclosed
- Jul 1, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
IBRX since disclosure
−0.2%
after the sale
Similar stocks (XLV) since disclosure
+10.8%
XLV — its sector index fund
Change in closing price from Jul 1, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLChristobel Selecky DirectorIBRX ImmunityBio, Inc.$9Kdisclosed Jul 1 · filed 1 day after the trade